Profile data is unavailable for this security.
About the company
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
- Revenue in USD (TTM)1.28bn
- Net income in USD-222.15m
- Incorporated2015
- Employees2.90k
- LocationLivaNova PLC20 Eastbourne TerraceLONDON W2 6LGUnited KingdomGBR
- Phone+44 203 325 0662
- Websitehttps://www.livanova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AtriCure Inc | 480.08m | -38.18m | 1.52bn | 1.30k | -- | 3.34 | -- | 3.17 | -0.8101 | -0.8101 | 10.19 | 9.19 | 0.8115 | 1.65 | 8.09 | 369,289.20 | -6.45 | -3.84 | -7.20 | -4.25 | 74.76 | 74.53 | -7.95 | -7.13 | 2.88 | -21.61 | 0.1335 | -- | 16.55 | 15.05 | -46.85 | -- | 14.00 | -- |
| 10X Genomics Inc | 624.66m | -157.04m | 1.58bn | 1.31k | -- | 2.23 | -- | 2.52 | -1.30 | -1.30 | 5.15 | 5.74 | 0.6841 | 2.50 | 8.68 | 478,301.70 | -17.20 | -25.61 | -19.51 | -29.19 | 68.36 | 74.03 | -25.14 | -47.52 | 4.68 | -- | 0.00 | -- | -1.28 | 19.96 | 28.41 | -- | -20.72 | -- |
| Conmed Corp | 1.32bn | 118.75m | 1.59bn | 3.90k | 13.44 | 1.62 | 8.31 | 1.21 | 3.82 | 3.82 | 42.27 | 31.61 | 0.5713 | 1.71 | 5.69 | 337,435.40 | 5.16 | 1.85 | 5.89 | 2.11 | 56.14 | 55.15 | 9.02 | 3.44 | 1.00 | 5.04 | 0.4771 | 63.56 | 5.00 | 6.47 | 105.44 | 35.85 | -8.20 | 0.00 |
| Alphatec Holdings Inc | 642.27m | -165.54m | 1.61bn | 867.00 | -- | -- | -- | 2.50 | -1.15 | -1.15 | 4.45 | -0.4243 | 0.8234 | 1.23 | 7.01 | 740,790.10 | -21.22 | -27.43 | -26.85 | -34.69 | 68.96 | 66.99 | -25.77 | -39.40 | 1.67 | -11.66 | 1.13 | -- | 26.81 | 40.07 | 13.14 | -- | 48.19 | -- |
| Premier Inc | 1.10bn | 104.27m | 1.74bn | 2.90k | 20.85 | 1.14 | 7.42 | 1.58 | 1.01 | 0.5705 | 11.31 | 18.50 | 0.3419 | -- | 2.51 | 379,330.30 | 3.58 | 7.08 | 4.78 | 8.95 | 70.96 | 61.29 | 10.48 | 16.05 | -- | -- | 0.38 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| UFP Technologies Inc | 547.56m | 63.47m | 1.87bn | 4.15k | 29.76 | 5.18 | 23.44 | 3.41 | 8.15 | 8.15 | 70.31 | 46.80 | 1.04 | 4.75 | 7.06 | 132,069.50 | 12.09 | 10.12 | 13.83 | 11.53 | 28.99 | 27.07 | 11.59 | 10.64 | 1.45 | 8.86 | 0.3364 | 0.00 | 26.08 | 20.52 | 31.29 | 24.46 | 10.82 | -- |
| LeMaitre Vascular Inc | 226.26m | 45.16m | 1.89bn | 651.00 | 42.34 | 5.44 | 34.38 | 8.36 | 1.98 | 1.98 | 9.90 | 15.38 | 0.4973 | 1.12 | 6.92 | 347,551.50 | 9.93 | 9.09 | 10.52 | 9.89 | 68.80 | 66.24 | 19.96 | 16.64 | 13.83 | -- | 0.3258 | 38.38 | 13.63 | 13.40 | 46.28 | 19.68 | 13.11 | 13.79 |
| Enovis Corp | 2.15bn | -811.94m | 1.94bn | 7.37k | -- | 0.7425 | -- | 0.9041 | -14.52 | -14.47 | 38.53 | 45.83 | 0.4154 | 1.63 | 5.27 | 291,867.90 | -15.67 | -3.14 | -17.40 | -3.56 | 55.68 | 52.01 | -37.72 | -9.77 | 1.32 | 0.9747 | 0.3462 | -- | 23.46 | -8.73 | -1,423.10 | -- | 7.58 | -- |
| Novocure Ltd | 621.71m | -164.19m | 1.96bn | 1.49k | -- | 5.42 | -- | 3.16 | -1.51 | -1.51 | 5.72 | 3.25 | 0.5246 | 3.47 | 8.31 | 417,816.50 | -13.85 | -9.61 | -22.39 | -11.84 | 77.16 | 77.57 | -26.41 | -19.32 | 1.41 | -- | 0.6446 | -- | 18.82 | 11.49 | 18.55 | -- | 32.52 | -- |
| Quidelortho Corp | 2.76bn | -358.70m | 2.05bn | 6.60k | -- | 0.6833 | 23.61 | 0.7421 | -5.33 | -5.33 | 41.05 | 44.40 | 0.42 | 2.56 | 8.74 | 418,893.90 | -5.45 | 0.0044 | -6.33 | 0.005 | 46.94 | 59.13 | -12.97 | 0.009 | 0.6637 | 0.535 | 0.4548 | 0.00 | -7.17 | 39.07 | -20,216.83 | -- | 48.27 | -- |
| LivaNova PLC | 1.28bn | -222.15m | 2.42bn | 2.90k | -- | 2.34 | -- | 1.90 | -4.09 | -4.09 | 23.37 | 18.97 | 0.5083 | 2.55 | 6.20 | 439,786.20 | -8.85 | -4.14 | -11.25 | -5.03 | 69.33 | 67.61 | -17.42 | -9.04 | 1.37 | -- | 0.3781 | -- | 8.66 | 2.94 | 260.39 | -- | 10.98 | -- |
| Warby Parker Inc | 795.09m | -14.24m | 2.70bn | 2.22k | -- | 7.61 | 81.17 | 3.39 | -0.1188 | -0.1188 | 6.53 | 2.92 | 1.25 | 6.77 | 602.34 | 358,473.40 | -2.23 | -16.02 | -2.75 | -21.00 | 55.26 | 56.59 | -1.79 | -13.26 | 2.30 | -- | 0.00 | -- | 15.16 | 15.80 | 67.74 | -- | 14.43 | -- |
| Procept Biorobotics Corp | 249.12m | -90.19m | 3.13bn | 756.00 | -- | 8.05 | -- | 12.58 | -1.70 | -1.70 | 4.69 | 7.04 | 0.5522 | 1.79 | 3.68 | 329,525.10 | -19.99 | -26.94 | -22.23 | -29.81 | 62.71 | 54.37 | -36.20 | -83.14 | 7.75 | -- | 0.1169 | -- | 64.84 | 105.21 | 13.68 | -- | -10.34 | -- |
| DENTSPLY SIRONA Inc | 3.72bn | -908.00m | 3.23bn | 14.00k | -- | 1.61 | -- | 0.8687 | -4.54 | -4.54 | 18.48 | 10.09 | 0.5646 | 2.92 | 5.90 | 265,642.80 | -13.79 | -4.06 | -18.07 | -4.83 | 51.84 | 53.14 | -24.42 | -8.59 | 0.7619 | 6.78 | 0.5374 | -- | -4.34 | -1.17 | -589.39 | -- | 7.91 | 11.28 |
| ICU Medical Inc | 2.42bn | -93.69m | 3.25bn | 15.00k | -- | 1.64 | 26.88 | 1.34 | -3.83 | -3.83 | 98.92 | 80.76 | 0.5713 | 2.45 | 15.31 | 161,339.50 | -2.21 | -0.2042 | -2.51 | -0.2306 | 35.11 | 33.82 | -3.87 | -0.3326 | 1.52 | 1.22 | 0.4365 | -- | 5.44 | 13.47 | -296.86 | -- | -3.18 | -- |
| Envista Holdings Corp | 2.50bn | -1.12bn | 3.42bn | 12.30k | -- | 1.14 | -- | 1.37 | -6.53 | -6.53 | 14.49 | 17.70 | 0.4165 | 4.28 | 6.21 | 203,569.10 | -18.70 | -2.08 | -21.69 | -2.53 | 54.77 | 56.91 | -44.90 | -5.58 | 1.82 | 3.40 | 0.3174 | -- | -2.18 | 1.90 | -1,016.37 | -- | -15.36 | -- |
Data as of Jul 11 2025. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD
46.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.53m | 12.01% |
| PRIMECAP Management Co.as of 31 Mar 2025 | 4.61m | 8.48% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.56m | 4.72% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 2.10m | 3.86% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 2.08m | 3.82% |
| Millennium Management LLCas of 31 Mar 2025 | 2.07m | 3.80% |
| AQR Capital Management LLCas of 31 Mar 2025 | 1.57m | 2.89% |
| Geode Capital Management LLCas of 31 Mar 2025 | 1.41m | 2.60% |
| Dimensional Fund Advisors LPas of 31 Mar 2025 | 1.23m | 2.26% |
| Marshall Wace LLPas of 31 Mar 2025 | 1.11m | 2.04% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
